瑞舒伐他汀对冠心病合并慢性心力衰竭患者临床疗效及血浆脑钠肽的影响.pdfVIP

瑞舒伐他汀对冠心病合并慢性心力衰竭患者临床疗效及血浆脑钠肽

的影响

目的观察瑞舒伐他汀对冠心病合并慢性心力衰竭患者(CHF)临床疗效及

血浆脑钠肽(BNP)水平的影响。方法80例冠心病并CHF患者随机分为治疗组和

对照组各40例,对照组患者给予抗心力衰竭的常规治疗;治疗组在对照组基础上

加用瑞舒伐他汀钙治疗,每晚餐时服用20mg,1次/d。两组均治疗6个月。两组分

别于治疗前及治疗6个月后测定左室心功能指标及血浆BNP水平。同时观察临

床症状、体征及药物不良反应。结果治疗6个月后治疗组总有效率显著高于对

照组(P＜0.05);治疗组的心功能指标及血浆BNP水平的改善均优于对照组(P＜

0.05,或P＜0.01)。结论CHF患者在常规治疗同时加用瑞舒伐他汀治疗,可以显

著降低血浆BNP水平,改善心功能。

【Abstract】ObjectiveToobservetheeffectsofrosuvastatinonpatientswith

coronayrheartdiseasecomplicatedchronicheartfailure(CHF)onwithclinicaland

plasmabrainnatriureticpeptide(BNP)levels.Methods80patientswithcoronary

heartdiseasewererandomlydividedintotreatmentgroup(40cases)andcontrol

group(40cases),thecontrolgroupweretreatedwithanti-heartfailureofconventional

treatment;thetreatmentgroupwasaddedRosuvastatincalciumtreatmentonthebasis

ofthecontrolgroup,eachdinnertaking20mg,onceaday,Bothgroupsweretreatedfor

6months.TheleftventricularcardiacfunctionandplasmaBNPlevelsweremeasured

beforetreatmentandafter6monthstreatment.Whileobservingtheclinical

symptoms,signs,andadversedrugreactions.ResultsAfter6monthstreatmentthetotal

effectiverateofthetreatmentgroupwassignificantlyhigherthanthatofthecontrol

group(P＜0.05);theindicatorsofcardiacfunctionandplasmaBNPlevelsimproved

comparedwiththecontrolgroup(P＜0.05,orP＜0.01).ConclusionCHFpatients

increaseswithrosuvastatintreatmentintheconventionaltreatmentatthesame

time,cansignificantlyreduceplasmaBNPlevels,improveheartfunction.

【Keywords】Rosuvastatin;Coronaryheartdisease;Chronicheartfailure;Brain

natriureticpeptide

他汀类药物在心血管疾病中的应用范围日益扩大。随着研究的深入,发现他

汀类药物具有除降血脂以外的心血管系统多效性作用,短期使用他汀类药物能改

善CHF患者的心功能和症状,纠正神经内分泌失调[1]。BNP是目前临床诊断CHF

的重要生化指标,对CHF的诊断、预后评估及疗效评定有非常重要的意义[2]。本

研究旨